Laurent Meijer

38.8k citations

378 papers · 27.8k indexed · 9 hit papers · h-index 84

Molecular Biology top 0.1%
Organic Chemistry top 0.1%
Oncology top 0.2%
Cell Biology top 0.1%
Public Health, Environmental and Occupational Health top 0.5%

Co-authors: Paul Greengard Olivier Lozach Sophie Leclerc Ali H. Brivanlou Léandros Skaltsounis Maryse Leost Noboru Sato Marie Knockaert
Topics: Cancer-related Molecular Pathways (96 papers)Microtubule and mitosis dynamics (63 papers)Quinazolinone synthesis and applications (50 papers)
Cited by: Toxicology Organic Chemistry Cell Biology
Journals: Nature Science Cell
Partner nations: France United States Germany

In The Last Decade

Laurent Meijer

375 papers receiving 27.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor

2003 1.7k citations Laurent Meijer et al. profile →
Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin‐Dependent Kinases cdc2, cdk2 and cdk5

1997 1.2k citations Laurent Meijer et al. profile →
Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

1999 682 citations Jane Endicott, Laurent Meijer et al. profile →
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors

1998 676 citations Laurent Meijer, Sung‐Hou Kim et al. profile →
GSK-3-Selective Inhibitors Derived from Tyrian Purple Indirubins

2003 672 citations Laurent Meijer et al. profile →
Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5/P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease

2001 635 citations Laurent Meijer et al. profile →
Inhibition of Cyclin‐Dependent Kinases by Purine Analogues

1997 619 citations Laurent Meijer et al. profile →
Inhibition of Cyclin‐Dependent Kinases by Purine Analogues

1994 562 citations Laurent Meijer et al. profile →
cdc2 is a component of the M phase-specific histone H1 kinase: Evidence for identity with MPF

1988 488 citations Laurent Meijer et al. profile →

Peers

Countries citing papers authored by Laurent Meijer

Since Specialization

Citations

This map shows the geographic impact of Laurent Meijer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurent Meijer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurent Meijer more than expected).

Fields of papers citing papers by Laurent Meijer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurent Meijer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurent Meijer. The network helps show where Laurent Meijer may publish in the future.

Co-authorship network of co-authors of Laurent Meijer

This figure shows the co-authorship network connecting the top 25 collaborators of Laurent Meijer. A scholar is included among the top collaborators of Laurent Meijer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurent Meijer. Laurent Meijer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of Tertiary Amine Selection on CO ₂ to Formic Acid Hydrogenation with the Au-np Catalyst 2025 ·Industrial & Engineering Chemistry Research ·(unknown),Laurent Meijer,(unknown),(unknown),Pierre Olivier,J. van der Schaaf	1
2	Restoring amyloid-β42 and γ-secretase function in Alzheimer’s disease 2025 ·Brain ·Alberto J. Espay,Kariem Ezzat,Kasper P. Kepp,Timothy Daly,Nikolaos K. Robakis,Laurent Meijer,Bruno P. Imbimbo	0
3	DYRK1A inhibition restores pancreatic functions and improves glucose metabolism in a preclinical model of type 2 diabetes 2025 ·Molecular Metabolism ·(unknown),Stéfania Tolu,(unknown),Cécile Tourrel‐Cuzin,(unknown),Julien Dairou,(unknown),Mattias F. Lindberg,Laurent Meijer,Jamileh Movassat,Benjamin Uzan	1
4	The protein kinase CK1: Inhibition, activation, and possible allosteric modulation 2022 ·Frontiers in Molecular Biosciences ·(unknown),Laurent Meijer,Marc Flajolet	11
5	Structural analogues of roscovitine rescue the intracellular traffic and the function of ER-retained ABCB4 variants in cell models 2019 ·Scientific Reports ·Virginie Vauthier,(unknown),(unknown),Nassima Oumata,Anne‐Marie Durand‐Schneider,Alix Bruneau,J. Delaunay,Chantal Housset,Tounsia Aït‐Slimane,Laurent Meijer,Thomas Falguières	15
6	Development of Kinase Inhibitors via Metal-Catalyzed C–H Arylation of 8-Alkyl-thiazolo[5,4-f]-quinazolin-9-ones Designed by Fragment-Growing Studies 2018 ·Molecules ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Pascal Bonnet,Laurent Meijer,Corinne Fruit,Thierry Besson	6
7	Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives 2016 ·Bioorganic & Medicinal Chemistry Letters ·Waël Zeinyeh,(unknown),Lionel Nauton,Nadège Loaëc,Laurent Meijer,Vincent Théry,Fabrice Anizon,F Giraud,Pascale Moreau	17
8	Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors. 2014 ·HAL (Le Centre pour la Communication Scientifique Directe) ·(unknown),Guy Fournet,Olivier Lozach,Lionel Perrin,Laurent Meijer,Benoı̂t Joseph	11
9	Indirubin Derivative 6BIO Suppresses Metastasis 2013 ·Cancer Research ·Simone Braig,Christine A. Kressirer,Johanna Liebl,(unknown),Stefan Zahler,Laurent Meijer,Angelika M. Vollmar	38
10	Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells 2013 ·Clinical Cancer Research ·Emilio Cosimo,Alison M. McCaig,(unknown),Helen Wheadon,(unknown),(unknown),Christian Berthou,Émilie Durieu,Nassima Oumata,Hervé Galons,Laurent Meijer,Alison M. Michie	28
11	CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD 2012 ·Cell Cycle ·Nikolay O. Bukanov,Sarah Moreno,Thomas A. Natoli,(unknown),Laurie A. Smith,Steven Ledbetter,Nassima Oumata,Hervé Galons,Laurent Meijer,Oxana Ibraghimov‐Beskrovnaya	51
12	Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5/p25 2010 ·Bioorganic & Medicinal Chemistry ·Prashi Jain,Patrick T. Flaherty,(unknown),Ishveen Chopra,(unknown),(unknown),Yoan Ferandin,Laurent Meijer,Jeffry D. Madura	19
13	N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine 2008 ·Molecular Cancer Therapeutics ·Karima Bettayeb,(unknown),Yoan Ferandin,Florence Popowycz,(unknown),Moustapha Hassan,Aude Echalier,Philippe Bernard,Jane Endicott,Benoı̂t Joseph,Laurent Meijer	47
14	7-Bromoindirubin-3′-oxime uncovers a serine protease-mediated paradigm of necrotic cell death 2008 ·Biochemical Pharmacology ·Judit Ribas,Vı́ctor J. Yuste,(unknown),Laurent Meijer,Josep E. Esquerda,Jacint Boix	21
15	Rebeccamycin Derivatives as Dual DNA-Damaging Agents and Potent Checkpoint Kinase 1 Inhibitors 2008 ·Molecular Pharmacology ·Christelle Marminon,Fabrice Anizon,Pascale Moreau,Bruno Pfeiffer,Alain St. Pierre,Roy M. Golsteyn,Paul Peixoto,Marie‐Paule Hildebrand,Marie‐Hélène David‐Cordonnier,Olivier Lozach,Laurent Meijer,Michelle Prudhomme	16
16	Meriolins, a New Class of Cell Death–Inducing Kinase Inhibitors with Enhanced Selectivity for Cyclin-Dependent Kinases 2007 ·Cancer Research ·Karima Bettayeb,Òscar M. Tirado,Séverine Marionneau‐Lambot,Yoan Ferandin,Olivier Lozach,Jonathan C. Morris,Silvia Mateo‐Lozano,Peter Drueckes,Christoph Schächtele,Michael H.G. Kubbutat,François Mouton‐Liger,Bernard Marquet,Benoı̂t Joseph,Aude Echalier,Jane Endicott,Vicente Notario,Laurent Meijer	95
17	The cell division cycle and its regulation 2006 ·Bulletin du Cancer ·Laurent Meijer	2
18	Le cycle de division cellulaire et sa régulation 2006 ·Bulletin du Cancer ·Laurent Meijer	7
19	Thiazolo[5,4-f]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3 2006 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Cédric Logé,(unknown),Jean‐Michel Robert,Olivier Lozach,(unknown),Laurent Meijer,Valérie Thiéry,Thierry Besson	52
20	Chemical inhibitors of cyclin-dependent kinases 1997 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Laurent Meijer,Sung‐Hou Kim	121

About Laurent Meijer

Laurent Meijer is a scholar working on Toxicology, Organic Chemistry and Cell Biology, having authored 378 papers that have together received 27.8k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (96 papers), Microtubule and mitosis dynamics (63 papers) and Quinazolinone synthesis and applications (50 papers). The work is most often cited by research in Toxicology (871 citations), Organic Chemistry (7.0k citations) and Cell Biology (4.0k citations). Laurent Meijer has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Paul Greengard, Olivier Lozach, Sophie Leclerc, Ali H. Brivanlou, Léandros Skaltsounis, Maryse Leost, Noboru Sato, Marie Knockaert, Annie Borgne and Yoan Ferandin. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact